Skip to content
Review Open access

Tertiary lymphoid structure topotypes in intrahepatic cholangiocarcinoma: spatial immunity, checkpoint-response associations, and therapeutic reprogramming

Aug 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 67 references
Medicine

TL;DR

This review provides a framework for biomarker development, therapeutic reprogramming, prospective validation, and longitudinal monitoring in ICC and distinguishes candidate circuit-competent, tumor-accessible TLS states from stromally excluded or suppressive-neighborhood states while allowing mixed profiles.

Abstract

Tertiary lymphoid structures (TLS) have evolved from descriptive histological findings into candidate biomarkers and targetable immune niches in solid tumors. In intrahepatic cholangiocarcinoma (ICC), however, similar lymphoid architectures may have different biological implications depending on their relationship to tumor nests, immune circuitry, and suppressive stroma. We define a “TLS topotype” as the multidimensional state of an individual TLS-centered region, including the TLS core, its perilesional neighborhood, and the nearest tumor–stroma interface. This state integrates anatomic topology and tumor accessibility, structural maturity, putative effector circuitry, and suppressive context; treatment-induced plasticity is considered separately through longitudinal assessment. Because heterogeneous TLS may coexist within one tumor, the whole tumor is represented by a “topotype landscape” based on compartment-specific TLS density and the distribution of TLS-level states rather than a single label. Direct human ICC evidence supports compartment-resolved associations between TLS distribution and outcome and identifies suppressive B-cell, Treg, myeloid, and stromal programs. These observations establish spatial TLS organization as prognostically relevant, but do not validate the framework or demonstrate treatment-specific prediction. By contrast, TLS-resident TCF7-positive stem-like CD8 T-cell maintenance, coordinated B-cell–dendritic-cell–T-cell circuitry, and ICI-specific predictive value remain unproven in ICC and should be considered hypothesis-generating. The framework therefore distinguishes candidate circuit-competent, tumor-accessible TLS states from stromally excluded or suppressive-neighborhood states while allowing mixed profiles. Multiplex pathology and spatial transcriptomics may define these states, whereas radiomics, liquid biopsy, and pretreatment biopsy provide complementary but incomplete information. Biopsy can characterize only TLS states captured in sampled tissue, and radiomics currently estimates whole-lesion TLS probability rather than functional topology. Marker expression or spatial colocalization alone does not establish functional productivity, which requires evidence of tumor-antigen presentation or specificity, local lymphocyte renewal or clonal expansion, functional perturbation, or a spatially linked treatment response. By separating TLS-level state, tumor-level landscape, and patient-level trial stratum, this review provides a framework for biomarker development, therapeutic reprogramming, prospective validation, and longitudinal monitoring in ICC. No TLS topotype has yet been validated to predict differential benefit from immune checkpoint inhibition in ICC.

Read PDF

Similar papers

Review Open access Sep 2026

Metabolite-driven dysfunction of intratumoral tertiary lymphoid structures: single-cell and spatial omics perspectives on cancer immune escape

This work proposes that metabolite-driven remodeling of the tumor microenvironment is a major cause of intratumoral TLS failure and outlines biomarker-guided strategies to restore TLS competence, including inhibition of tumor-derived tryptophan metabolism to promote TLS maturation and enhance anti-PD-1 efficacy.

Yi-Feng Wang, Yan Li, Shu-Juan Wei et al. · 0 citations
Review Open access Oct 2026

Multi-omics of tertiary lymphoid structures in breast cancer: clinical significance and biomarker potential

Background Tertiary lymphoid structures (TLSs) are organized immune aggregates that can support local adaptive immune responses within the tumor microenvironment. In breast cancer, particularly triple-negative breast cancer (TNBC), the presence and maturation of TLSs have been associated with prognosis and treatment re...

Chang-Huan Chen, Hai-Ping Song · 0 citations
Review Open access Nov 2026

Tertiary lymphoid structures in luminal gastrointestinal cancers: biological circuits, spatial architecture, and biomarkers in the perioperative immunotherapy era

Tertiary lymphoid structures (TLS) are inducible, organized lymphoid clusters that recapitulate key functions of secondary lymphoid organs within chronically inflamed tumor tissue. In colorectal, gastric, and esophageal cancers, the most common luminal gastrointestinal (GI) malignancies, surgical resection preserves th...

Song-Lin Sun, Jia-Han Chen, Yang Zhong et al. · 0 citations
Review Open access Oct 2026

From density to spatial function: spatial multi-omics, composite biomarker design, and therapeutic engineering of tertiary lymphoid structures in solid tumors

This review synthesizes recent advances in spatial biology that support a shift from counting TLSs to interpreting them as spatially organized immune microenvironmental units embedded within local tumor ecosystems and outlines a staged, module-matched composite biomarker workflow combining digital pathology, targeted m...

Xu-Chen Wang, Lin Lin · 0 citations
Review Open access Sep 2026

Non-immune regulation of tertiary lymphoid structures in cancer

The promise of non-immune components as rational targets for combination strategies to enhance TLS function and immunotherapy efficacy is discussed, suggesting that these structures function as emergent tissue ecosystems rather than as immune aggregates alone.

Owen K. Challen, Evelyn Fitzsimons, W. Anderson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.